Assessing the essentiality of leishmania donovani nitroreductase and its role in nitro drug activation

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 901-906

  Wyllie, Susan ^a   Patterson, Stephen ^a   Fairlamb, Alan H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FEXINIDAZOLE; MILTEFOSINE; NIFURTIMOX; NITROFURAL; NITROREDUCTASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE; GENE DOSAGE; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENOTYPE; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; NTR GENE; PARASITE SURVIVAL; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROMASTIGOTE; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI;

CELL LINE; DRUG RESISTANCE; GENE KNOCKOUT TECHNIQUES; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; NITRO COMPOUNDS; NITROIMIDAZOLES; NITROREDUCTASES; TRYPANOCIDAL AGENTS;

EID: 84872869569     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01788-12     Document Type: Article

References (20)

1. Ritmeijer K, Davidson RN. 2003. Medecins Sans Frontières interventions against kala-azar in the Sudan, 1989-2003. Trans. R. Soc. Trop. Med. Hyg. 97:609-613.
2. Regional Technical Advisory Group on Kala-azar Elimination. 2005. Report of the first meeting, Manesar, Haryana, 20-23 December 2004. WHO project IND CDR 714. SEA-VBC-88. World Health Organization Regional Office for South-East Asia, New Delhi, India. http://www.searo .who.int/LinkFiles/Kala-azar-VBC-88.pdf.
3. den Boer ML, Alvar J, Davidson RN, Ritmeijer K, Balasegaram M. 2009. Developments in the treatment of visceral leishmaniasis. Expert Opin. Emerg. Drugs 14:395-410.
4. Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR, Davidson R. 2007. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans. R. Soc. Trop. Med. Hyg. 101:19-24.
5. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande V. 2009. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: A multicentre, randomised, phase III, non-inferiority trial. Lancet 374:56-64.
6. Jennings FW, Urquhart GM. 1983. The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice. Z. Parasitenkd. 69:577-581.
7. Torreele E, Trunz BB, Tweats D, Kaiser M, Brun R, Mazue G, Bray MA, Pecoul B. 2010. Fexinidazole-a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl. Trop. Dis. 4:e923. doi:10.1371/journal.pntd.0000923.
8. Wyllie S, Patterson S, Stojanovski L, Simeons FR, Norval S, Kime R, Read KD, Fairlamb AH. 2012. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci. Transl. Med. 4:119re1. doi:10.1126/scitranslmed.3003326.
9. Hall BS, Bot C, Wilkinson SR. 2011. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 286:13088-13095.
10. Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. 2008. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. U. S. A. 105:5022-5027.
11. Goyard S, Segawa H, Gordon J, Showalter M, Duncan R, Turco SJ, Beverley SM. 2003. An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. Mol. Biochem. Parasitol. 130:31-42.
12. Jones DC, Hallyburton I, Stojanovski L, Read KD, Frearson JA, Fairlamb AH. 2010. Identification of a kappa-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochem. Pharmacol. 80:1478-1486.
13. Martin K, Smith TK. 2005. The myo-inositol-1-phosphate synthase gene is essential in Trypanosoma brucei. Biochem. Soc. Trans. 33:983-985.
14. Gaur U, Showalter M, Hickerson S, Dalvi R, Turco SJ, Wilson ME, Beverley SM. 2009. Leishmania donovani lacking the Golgi GDP-Man transporter LPG2 exhibit attenuated virulence in mammalian hosts. Exp. Parasitol. 122:182-191.
15. Sokolova AY, Wyllie S, Patterson S, Oza SL, Read KD, Fairlamb AH. 2010. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob. Agents Chemother. 54: 2893-2900.
16. Brandt U. 2006. Energy converting NADH:quinone oxidoreductase (complex I). Annu. Rev. Biochem. 75:69-92.
17. Alsford S, Eckert S, Baker N, Glover L, Sanchez-Flores A, Leung KF, Turner DJ, Field MC, Berriman M, Horn D. 2012. High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 482: 232-236.
18. Mejia AM, Hall BS, Taylor MC, Gomez-Palacio A, Wilkinson SR, Triana-Chavez O, Kelly JM. 2012. Benznidazole resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population. J. Infect. Dis. 206:220-228.
19. White NJ, Olliaro PL. 1996. Strategies for the prevention of antimalarial drug resistance: Rationale for combination chemotherapy for malaria. Parasitol. Today 12:399-401.
20. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F. 2011. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: An open-label, non-inferiority, randomised controlled trial. Lancet 377: 477-486.